LVADs not worth it as yet for end-stage HF in the UK

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1578, 2007-01, pp. : 5-5

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

LVADs not worth it as yet for end-stage HF in the UK

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 523, 2007-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

Epidemiology of end-stage renal disease

By Roderick Paul  

Clinical Medicine, Vol. 2, Iss. 3, 2002-05 ,pp. : 200-204

Royal College Of Physicians

Access to resources Recommend Favorite

Emerging drugs for complications of end-stage liver disease

By Dowman Joanna K   Holt Andrew P   Newsome Philip N   Adams David H  

Expert Opinion on Emerging Drugs, Vol. 13, Iss. 1, 2008-03 ,pp. : 159-174

Informa Healthcare

Access to resources Recommend Favorite

Pharmacotherapy for end-stage coronary artery disease

By Sodha Neel R   Chu Louis M   Boodhwani Munir   Sellke Frank W  

Expert Opinion on Pharmacotherapy, Vol. 11, Iss. 2, 2010-02 ,pp. : 207-213

Informa Healthcare

Access to resources Recommend Favorite

Anorexia in end-stage renal disease: pathophysiology and treatment

By Alvarez Vicente   Diéz Juan Jose   Aguilera Abelardo   Selgas Rafael   Codoceo Rosa   Bajo Maria A  

Expert Opinion on Pharmacotherapy, Vol. 2, Iss. 11, 2001-11 ,pp. : 1825-1838

Informa Healthcare

Access to resources Recommend Favorite